{"disease":{"id":"keratoconjunctivitis-sicca","name":"Keratoconjunctivitis sicca","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ciclosporin","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"cyclosporine","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"ciclosporine","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"neoral","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclosporin","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03925727","title":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":623,"lead_sponsor_name":"Mimetogen Pharmaceuticals USA, Inc.","has_results":true},{"nct_id":"NCT01421498","title":"Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04147650","title":"Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Aurinia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04421300","title":"A Randomized Study of Smile Exercise for Dry Eye","phase":"NA","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT02845674","title":"An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT01817582","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT02526290","title":"Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator","phase":"NA","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT04493658","title":"Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04884217","title":"Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"PharmaDax Inc.","has_results":false},{"nct_id":"NCT02117687","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03418259","title":"Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05891106","title":"AONDA Therapeutic Indication Study I","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT02680158","title":"A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT07422259","title":"Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Medivis SRL","has_results":false},{"nct_id":"NCT04615455","title":"Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05918406","title":"Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Oyster Point Pharma, Inc.","has_results":true},{"nct_id":"NCT02970799","title":"Tear Production by Nasal Neurostimulation Compared to Active Control","phase":"NA","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT03706443","title":"Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT03436576","title":"Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT05618730","title":"Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Eximore Ltd.","has_results":false},{"nct_id":"NCT03953703","title":"Levocarnitine for Dry Eye in Sjogren's Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT04649177","title":"Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting","phase":"NA","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Boston Sight","has_results":true},{"nct_id":"NCT01226680","title":"A Study Of Tasocitinib In Dry Eye Subjects","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03398018","title":"Repository Corticotropin Injection in Keratoconjunctivitis Sicca","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}